ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ATR
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ATR
4
trial(s) found.
NCT06433219
Advanced
Phase 2
Recruiting
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302) (
MS201924-0002
)
ATM inhibitor
ATR inhibitor
PARP inhibitor
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
NCT06421935
Advanced
Phase 1
Recruiting
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors (
MS202659-0001
)
PARP1-selective inhibitor
+ ATR inhibitor
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
NCT05269316
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors (
IMP9064-101
)
ATR inhibitor
PARP inhibitor
NOT Central nervous system cancer
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research (COMPLETED)
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ ATR inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Status unknown (1)
Recruitment Country and State
NSW (3)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (1)
Trial Type
Advanced (4)
Cancer Therapy Class
ATR
100%
PARP
75%
ATM
25%
CYP17A1
25%
PARP1-selective
25%
androgen axis
25%
ALK
25%
BCR-ABL1
25%
CDK4
25%
CDK6
25%
CRAF
25%
EGFR
25%
FLT3
25%
JAK1
25%
JAK2
25%
KIT
25%
MET
25%
PDGFR
25%
PDGFRA
25%
PI3K
25%
RAF
25%
ROS1
25%
SMO
25%
SRC
25%
VEGFR
25%
YES1
25%
mTOR
25%
mTORC1
25%
mTORC2
25%
Facility
2170 - Liverpool - Liverpool Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
Cancer Type
Cancer
Solid tumour
Gynaecological cancer
Ovarian cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy